vs
Ascendis Pharma A/S（ASND）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Ascendis Pharma A/S的季度营收约是STURM RUGER & CO INC的1.8倍（$267.3M vs $151.1M），Ascendis Pharma A/S同比增速更快（42.3% vs 3.6%），过去两年Ascendis Pharma A/S的营收复合增速更高（60.7% vs 5.1%）
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
ASND vs RGR — 直观对比
营收规模更大
ASND
是对方的1.8倍
$151.1M
营收增速更快
ASND
高出38.7%
3.6%
两年增速更快
ASND
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $267.3M | $151.1M |
| 净利润 | — | — |
| 毛利率 | 90.5% | 17.8% |
| 营业利润率 | — | 2.3% |
| 净利率 | — | — |
| 营收同比 | 42.3% | 3.6% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASNDRGR
| Q4 25 | $267.3M | $151.1M | ||
| Q3 25 | $230.7M | $126.8M | ||
| Q2 25 | $170.7M | $132.5M | ||
| Q1 25 | $109.0M | $135.7M | ||
| Q4 24 | $187.8M | $145.8M | ||
| Q3 24 | $62.5M | $122.3M | ||
| Q2 24 | $38.9M | $130.8M | ||
| Q1 24 | $103.6M | $136.8M |
净利润ASNDRGR
| Q4 25 | — | — | ||
| Q3 25 | $-65.9M | $1.6M | ||
| Q2 25 | $-42.0M | $-17.2M | ||
| Q1 25 | $-102.2M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-107.1M | $4.7M | ||
| Q2 24 | $-118.1M | $8.3M | ||
| Q1 24 | $-141.5M | $7.1M |
毛利率ASNDRGR
| Q4 25 | 90.5% | 17.8% | ||
| Q3 25 | 89.5% | 15.1% | ||
| Q2 25 | 80.1% | 3.9% | ||
| Q1 25 | 82.6% | 22.0% | ||
| Q4 24 | 91.9% | 22.8% | ||
| Q3 24 | 80.6% | 18.5% | ||
| Q2 24 | 68.2% | 22.3% | ||
| Q1 24 | 92.1% | 21.5% |
营业利润率ASNDRGR
| Q4 25 | — | 2.3% | ||
| Q3 25 | 5.1% | -2.7% | ||
| Q2 25 | -33.5% | -15.6% | ||
| Q1 25 | -103.2% | 6.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | -167.3% | 3.1% | ||
| Q2 24 | -370.2% | 6.9% | ||
| Q1 24 | -51.2% | 5.5% |
净利率ASNDRGR
| Q4 25 | — | — | ||
| Q3 25 | -28.5% | 1.2% | ||
| Q2 25 | -24.6% | -13.0% | ||
| Q1 25 | -93.7% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -171.5% | 3.9% | ||
| Q2 24 | -303.9% | 6.3% | ||
| Q1 24 | -136.6% | 5.2% |
每股收益（稀释后）ASNDRGR
| Q4 25 | — | $0.22 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | — | $-1.05 | ||
| Q1 25 | — | $0.46 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | — | $0.47 | ||
| Q1 24 | — | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.3M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-175.8M | $283.8M |
| 总资产 | $1.4B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASNDRGR
| Q4 25 | $665.3M | $92.5M | ||
| Q3 25 | $582.2M | $80.8M | ||
| Q2 25 | $533.6M | $101.4M | ||
| Q1 25 | $559.4M | $108.3M | ||
| Q4 24 | $604.3M | $105.5M | ||
| Q3 24 | $675.6M | $96.0M | ||
| Q2 24 | $279.4M | $105.6M | ||
| Q1 24 | $345.9M | $115.3M |
股东权益ASNDRGR
| Q4 25 | $-175.8M | $283.8M | ||
| Q3 25 | $-188.0M | $279.6M | ||
| Q2 25 | $-202.6M | $289.3M | ||
| Q1 25 | $-205.0M | $321.5M | ||
| Q4 24 | $-114.2M | $319.6M | ||
| Q3 24 | $-105.1M | $314.9M | ||
| Q2 24 | $-346.8M | $321.5M | ||
| Q1 24 | $-257.2M | $332.0M |
总资产ASNDRGR
| Q4 25 | $1.4B | $342.0M | ||
| Q3 25 | $1.2B | $342.3M | ||
| Q2 25 | $1.2B | $349.5M | ||
| Q1 25 | $1.1B | $379.0M | ||
| Q4 24 | $1.3B | $384.0M | ||
| Q3 24 | $1.2B | $373.5M | ||
| Q2 24 | $819.0M | $376.7M | ||
| Q1 24 | $866.7M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.2M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | — | $12.3M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
经营现金流ASNDRGR
| Q4 25 | $58.2M | $15.5M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | — | $14.7M | ||
| Q1 25 | $-15.5M | $11.1M | ||
| Q4 24 | $-330.7M | $20.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | $-109.7M | $7.3M |
自由现金流ASNDRGR
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
自由现金流率ASNDRGR
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
资本支出强度ASNDRGR
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 1.3% |
现金转化率ASNDRGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASND
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
